S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:RGNX

REGENXBIO - RGNX Stock Forecast, Price & News

$24.26
+0.72 (+3.06%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$23.02
$24.54
50-Day Range
$20.45
$26.43
52-Week Range
$18.69
$36.35
Volume
220,800 shs
Average Volume
388,837 shs
Market Capitalization
$1.05 billion
P/E Ratio
15.65
Dividend Yield
N/A
Price Target
$41.43

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
70.8% Upside
$41.43 Price Target
Short Interest
Healthy
6.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.75mentions of REGENXBIO in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.70) to ($3.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

90th out of 1,033 stocks

Biological Products, Except Diagnostic Industry

12th out of 170 stocks

RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

REGENXBIO (NASDAQ:RGNX) Trading Up 4%
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings
11/03/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+70.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$127.84 million
Pretax Margin
18.12%

Debt

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.35 per share
Book Value
$13.02 per share

Miscellaneous

Free Float
37,796,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
0.99

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 47)
    Pres, CEO & Director
    Comp: $1.72M
  • Mr. Vittal K. Vasista (Age 54)
    Exec. VP & Chief Financial Officer
    Comp: $1.25M
  • Mr. Curran M. Simpson M.S. (Age 60)
    Exec. VP and Chief Operations & Technology Officer
    Comp: $924.95k
  • Dr. Olivier Danos Ph.D. (Age 64)
    Exec. VP & Chief Scientific Officer
    Comp: $842.08k
  • Mr. Patrick J. Christmas II (Age 51)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Tricia Truehart
    VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost
    VP of Corp. Devel.
  • Ms. Shiva G. Fritsch
    Chief People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 69)
    Ph.D., Sr. VP of Intellectual Property
  • Dr. Ram Palanki Pharm.D.
    Sr. VP of Commercial Strategy & Operations













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

6 brokers have issued twelve-month target prices for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they predict the company's stock price to reach $41.43 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2022?

REGENXBIO's stock was trading at $32.70 at the start of the year. Since then, RGNX shares have decreased by 25.8% and is now trading at $24.26.
View the best growth stocks for 2022 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.55) by $0.20. The biotechnology company earned $26.51 million during the quarter, compared to analysts' expectations of $29.77 million. REGENXBIO had a net margin of 15.34% and a trailing twelve-month return on equity of 12.22%.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.13%), Vanguard Group Inc. (9.86%), State Street Corp (6.05%), Dimensional Fund Advisors LP (2.90%), Bioimpact Capital LLC (1.43%) and Bank of New York Mellon Corp (0.79%). Insiders that own company stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $24.26.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $1.05 billion and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 12/5/2022 by MarketBeat.com Staff